J. Safra Sarasin Holding AG Increases Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

J. Safra Sarasin Holding AG boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 87.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 25,189 shares of the medical equipment provider's stock after buying an additional 11,765 shares during the period. J. Safra Sarasin Holding AG's holdings in Zimmer Biomet were worth $2,661,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Dodge & Cox lifted its holdings in Zimmer Biomet by 12.0% in the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock worth $2,019,480,000 after purchasing an additional 2,044,645 shares in the last quarter. Van ECK Associates Corp boosted its position in shares of Zimmer Biomet by 5.9% during the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after acquiring an additional 218,688 shares during the last quarter. Franklin Resources Inc. grew its stake in Zimmer Biomet by 398.7% during the fourth quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock valued at $369,469,000 after acquiring an additional 2,796,372 shares in the last quarter. Norges Bank bought a new stake in Zimmer Biomet in the 4th quarter valued at $216,223,000. Finally, Dimensional Fund Advisors LP lifted its stake in Zimmer Biomet by 6.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,000,838 shares of the medical equipment provider's stock worth $211,348,000 after purchasing an additional 126,151 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Down 0.0 %

Shares of Zimmer Biomet stock traded down $0.04 on Friday, reaching $101.46. The stock had a trading volume of 1,661,962 shares, compared to its average volume of 1,665,077. The stock has a market capitalization of $20.07 billion, a P/E ratio of 22.80, a P/E/G ratio of 1.95 and a beta of 0.84. Zimmer Biomet Holdings, Inc. has a 1 year low of $93.10 and a 1 year high of $123.96. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company has a 50 day moving average price of $105.82 and a 200 day moving average price of $106.57.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the business earned $2.20 EPS. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.95%. Zimmer Biomet's dividend payout ratio is currently 21.57%.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Raymond James decreased their target price on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. JMP Securities reaffirmed a "market outperform" rating and set a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 7th. Barclays dropped their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Monday, February 10th. Finally, Truist Financial restated a "hold" rating and set a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $124.15.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company's stock, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.70% of the stock is currently owned by corporate insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.